A systematic analysis of the resistance and sensitivity of HER2YVMAreceptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer

Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study

(2015) Bei Yang et al.   JOURNAL OF MOLECULAR MODELING

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

(2014) Xinghao Ai et al.   AMINO ACIDS

Targeting EGFR mutants with non-cognate kinase inhibitors in non-small cell lung cancer

(2014) Bo Wang et al.   MEDICINAL CHEMISTRY RESEARCH

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

(2012) T Doi et al.   BRITISH JOURNAL OF CANCER

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

(2012) Fausto Petrelli et al.   Clinical Lung Cancer

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

(2011) Kathleen Aertgeerts et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

(2011) Chenguang Li et al.   Journal of Thoracic Oncology

Lung Cancer: Are we up to the Challenge?

(2010) Luca Esposito et al.   CURRENT GENOMICS

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third-Generation Tyrosine Kinase Inhibitors and Beyond

(2010) Alfonso Quintás-Cardama et al.   SEMINARS IN HEMATOLOGY

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib

(2008) T. M. Gilmer et al.   CANCER RESEARCH

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

(2008) H.-P. Kim et al.   MOLECULAR CANCER THERAPEUTICS